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Abstract
Hepatitis B virus (HBV) RNA in serum is a novel biomarker that reflects cccDNA 
activity. We investigated whether HBV RNA can predict serological response to 
peginterferon (PEG-IFN) treatment. Serum HBV RNA levels were retrospectively 
measured at weeks 0, 12, 24 and 52 of therapy and after treatment discontinua-
tion (week 78) in 266 HBeAg-positive chronic HBV patients who had participated in 
a global randomized controlled trial (HBV99-01 study). Patients received 52 weeks 
PEG-IFN monotherapy (n = 136) or PEG-IFN and lamivudine (n = 130). The primary 
end point was HBeAg loss 24 weeks after PEG-IFN discontinuation. At baseline, the 
mean serum level of HBV RNA was 6.8 (SD 1.2) log c/mL. HBV RNA levels declined 
to 4.7 (1.7) log c/mL after one year of PEG-IFN therapy alone and to 3.3 (1.2)log c/mL 
after combination therapy. From week 12 onward, HBV RNA level was significantly 
lower in patients who achieved HBeAg loss at the end of follow-up as compared to 
those who did not, regardless of treatment allocation (week 12:4.4 vs 5.1 log c/mL, 
P = .01; week 24:3.7 vs 4.9 log c/mL, P < .001). The performance of a multivariable 
model based on HBV RNA level was comparable at week 12 (AUC 0.68) and 24 (AUC 
0.72) of therapy. HBV RNA level above 5.5 log c/mL at week 12 showed negative 
predictive values of 93/67/90/64% for HBV genotypes A/B/C/D for the prediction 
of HBeAg loss. In conclusion, HBV RNA in serum declines profoundly during PEG-IFN 
treatment. Early on-treatment HBV RNA level may be used to predict nonresponse.
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1  | INTRODUC TION
Decades after the development of the first vaccine against hepatitis 
B virus (HBV), still almost one million individuals annually die due to 
acute or chronic HBV infection despite the available treatment strat-
egies.1 Eight FDA-approved drugs are currently available, including 
six nucleos(t)ide analogues (NA), pegylated interferon (PEG-IFN) 
alfa-2a and alfa-2b. PEG-IFN has anti-proliferative, immunomodula-
tory and antiviral effects, while NA directly inhibits the HBV poly-
merase.2 Although PEG-IFN treatment has a higher burden of side 
effects than NA treatment and is contraindicated in liver cirrhosis, 
its finite course and higher serological response rates makes it an 
interesting treatment option.3
However, one of the major limitations of currently available treat-
ment options for chronic HBV infection is that they do not silence or 
eliminate the main HBV replication template, the covalently closed 
circular DNA (cccDNA).4 Persistence of active cccDNA during or after 
treatment limits the achievement of a functional cure. In the devel-
opment of new therapeutic strategies, it therefore seems important 
to design agents that are able to interfere with cccDNA, but in order 
to reflect on the efficacy of these future agents, monitoring cccDNA 
activity is needed. Biomarkers reflecting cccDNA activity that can be 
obtained in a noninvasive way could play an important role.5 Studying 
these biomarkers in PEG-IFN treatment is needed because PEG-IFN 
is increasingly used in clinical studies of new therapeutic compounds, 
such as entry inhibitors.
HBV RNA in serum is a novel serum biomarker that can be 
measured using PCR techniques. Its nature has not been fully re-
searched, but it most likely comprises encapsidated pregenomic 
RNA (pgRNA).6,7 Pregenomic RNA is a more than whole-genome-
length transcript that is derived from the cccDNA directly and is 
transcribed by reverse transcriptase to form relaxed circular DNA 
(rcDNA), eventually leading to replenishment of the cccDNA pool 
and formation of HBV DNA containing particles. Therefore, HBV 
RNA in serum is assumed to reflect cccDNA activity, which was in-
deed observed in recent studies.8-10
During treatment with nucleos(t)ide (NA), early on-treatment lev-
els of HBV RNA were found to be a an early predictor for HBeAg loss 
and were superior to serum levels of HBV DNA or hepatitis B surface 
antigen (HBsAg) in this context.11,12 In a different, small population, a 
relation with HBsAg loss was observed.13 Fewer data are available on 
PEG-IFN treatment, but HBV RNA levels showed distinct dynamics in 
patients achieving HBeAg seroconversion.7
However, the studies describing these dynamics were based on 
uncontrolled populations, used different molecular methods and 
study different treatment end points. Therefore, we have studied HBV 
RNA levels and dynamics before and during PEG-IFN treatment in a 
well-defined, multi-ethnic population of HBeAg-positive individuals 
who were previously treated in a randomized controlled trial.
2  | PATIENTS AND METHODS
2.1 | Treatment regimen and study population
Serum levels of full-length polyadenylated HBV RNA were measured in 
available serum samples of 266 patients with HBeAg-positive chronic 
HBV infection who were treated within a previously conducted global 
randomized controlled trial (99-01 study). Detailed inclusion crite-
ria have been described elsewhere.11,14 In short, patients with active 
disease who had not received treatment ≥6 months prior to screen-
ing, did not have a coinfection and did not have a contraindication for 
PEG-IFN treatment were included. Patients received 52 weeks of PEG-
IFNalpha-2b and lamivudine (LAM) 100 mg or PEG-IFN alpha alone (1:1 
randomization). The dosage of PEG-IFN was 100 µg/wk from baseline 
through week 32 and was then decreased to 50 µg/wk to prevent early 
treatment discontinuation due to side effects. After treatment discon-
tinuation, all patients were followed for an additional 26 weeks.
2.2 | End points
Levels of HBV RNA were measured at baseline, week 12, 24, end of 
treatment (EOT, week 52) and end of follow-up (EOF, week 78). The 
primary end point was the association of serum HBV RNA levels and 
kinetics with loss of HBeAg or loss of HBsAg at the end of follow-up. 
We additionally aimed to validate a recently proposed HBV RNA cut-
off to identify those patients not achieving loss of HBeAg.11
2.3 | Serum HBV RNA quantification
Levels of polyadenylated HBV RNA were measured at a central labora-
tory (University Hospital Leipzig, Germany) from serum samples stored 
at −20°. For HBV RNA quantification, we used a rapid amplification of 
complimentary DNA (cDNA)-ends (RACE)-based real-time polymerase 
chain reaction (PCR) technique that has been previously described. 
Quantification of HBV RNA was performed using specific primers (in-
cluding HBV RNA RT primer 5′-ACC ACG CTA TCG CTA CTC AC (t17)
GWA GCT C) designed according to van Bömmel et al.15 The assay's 
lower limit of detection (LOD) for HBV RNA was 800 (2.9 log10) cop-
ies/mL (c/mL), with a corresponding linear range of 800 to 106 copies/
mL. HBV RNA levels below the LOD were set to 450 c/mL for statisti-
cal analysis.
K E Y W O R D S
chronic hepatitis B infection, functional cure, peginterferon treatment, serum marker, 
treatment response
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2.4 | Other laboratory measurements
Routine biochemical and haematological tests were performed at each 
individual site. Serum ALT levels were standardized by calculating the 
value times for the ULN per centre. Virological tests were performed 
at one central laboratory (Erasmus Medical Center). HBV DNA was 
measured using a in-house developed TaqMan-based PCR assay 
(Roche Diagnostics; lower limit of detection of 400 copies/mL). HBV 
DNA results in copies/mL were converted into IU/mL using a conver-
sion factor of 5.8 copies per IU. Serum qHBsAg levels were measured 
using the Architect HBsAg assay (Abbott Laboratories; range 0.05-
250 IU/mL). Serum HBeAg levels were quantified using the Cobas 
Elecsys HBeAg assay (Roche Diagnostics, measurement range 0.2-
100 IU/mL). HBV genotype analysis was performed using the INNO-
LiPA HBV genotype assay (Fujirebio Europe). The presence of PC and 
BCP mutants was assessed using the INNO-LiPA HBV PreCore assay 
(Fujirebio Belgium), which detects precore (PC) mutations at nucleo-
tide position 1896 and basal core promoter (BCP) mutations at nucleo-
tide positions 1762 and 1764. Results were classified into four groups: 
wild type (WT, only WT virus detectable), PC (only PC or both PC and 
WT detectable), BCP (either or both BCP mutations detected, with or 
without WT) or as PC + BCP when both types of mutants were found.
2.5 | Statistical analysis
SPSS version 25.0 (SPSS Inc) was used to perform statistical anal-
yses. Skewed laboratory values were log-transformed prior to 
analyses and were expressed as mean (standard deviation [SD]). 
Associations between variables were tested using Student's t 
test, chi-squared test, Pearson correlation or their nonparamet-
ric equivalents when appropriate. Subgroup analysis for mean 
HBV RNA levels at baseline was performed using ANOVA with 
Bonferroni correction for intergroup comparison. We performed 
logistic regression analysis to determine factors associated with 
response. The factors we included in univariable analysis were age, 
sex, HBV genotype, BCP and PC variants, presence of cirrhosis and 
treatment history. Factors that were found to be related (P < .20) 
were analysed in multivariable analysis. The performances of the 
retrieved prediction models were tested with receiver operating 
characteristic (ROC) curve analysis. All analyses were performed 
two-sided at the 0.05 level of significance.
3  | RESULTS
3.1 | Association of host and viral factors with HBV 
RNA levels at baseline
Patient characteristics are shown in Table 1. All major HBV geno-
types were represented. At baseline, the mean serum level of HBV 
RNA was 6.8 (SD 1.2) log c/mL. In one patient, HBV RNA was below 
LLD (28-year-old female patient, HBV genotype D, BCP mutant, 
HBV DNA 5.1 log IU/mL).HBV RNA level significantly correlated to 
HBV DNA (r = 0.66, P < .001), qHBsAg (r = 0.47, P < .001), qHBeAg 
(r = 0.29, P < .001) and ALT (r = 0.25 (P < .001). In multivariable lin-
ear regression analysis adjusting for ALT and presence of mutations, 
HBV RNA level at baseline was lowest in patients infected with HBV 
genotype C and highest in HBV genotype B (A/B/C/D: 6.6/7.2/ 6.2/ 







IFN + LAM 
(n = 130)
Demography
Age, years 35 (13) 36 (14) 34 (12)
Male, n (%) 20 (78) 107 (79) 100 (77)
Race, n (%)
Caucasian 196 (74) 101 (74) 95 (73)
Asian 53 (20) 29 (21) 24 (19)
Other 17 (6) 6 (5) 11 (8)
HBV genotype, n (%)
A 90 (34) 47 (35) 43 (33)
B 23 (9) 12 (9) 11 (9)
C 39 (15) 21 (15) 18 (14)
D 103 (38) 51 (38) 52 (40)
Other 11 (4) 5 (4) 6 (4)
BCP and PC variants, n (%)
Wildtype virus 75 (28) 40 (29) 35 (27)
PC mutation 56 (21) 25 (18) 31 (24)
BCP mutation 47 (18) 20 (15) 27 (21)
PC & BCP 
mutation
35 (13) 19 (14) 16 (12)
Cirrhosis, n (%) 24 (9) 11 (8) 13 (10)
Treatment history
Previous NA 33 (12) 16 (12) 17 (13)
Previous (PEG-)
IFN
55 (21) 28 (21) 27 (21)
Laboratory results
HBV RNA§  6.8 (1.2) 6.9 (1.2) 6.7 (1.2)
HBV DNA‡  8.3 (1.0) 8.3 (1.0) 8.3 (1.0)
qHBsAg‡  4.4 (0.6) 4.4 (0.6) 4.4 (0.6)
qHBeAg‡  2.4 (0.8) 2.4 (0.8) 2.4 (0.8)
ALT (×ULN)†  4.3 (3.5) 4.3 (3.1) 4.4 (3.9)
Note: Continuous variables are expressed as mean (SD), categorical 
variables as n (%).
Abbreviations: ALT, alanine aminotransferase; BCP, basal core 
promoter; HBV, hepatitis B virus; LLQ, lower limit of detection; NA, 
nucleos(t)ide analogue; (PEG-)IFN, (peg)interferon; PC, precore; 
qHBeAg, quantitative hepatitis B e antigen; qHBsAg, quantitative 
hepatitis B surface antigen; SD, standard deviation; ULN, upper limit of 
normal.
†Multiples of upper limit of the normal range. 
‡Logarithmic scale, IU/mL. 
§Logarithmic scale, c/mL. 
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7.0 log c/mL; C vs D P = .002, B vs C P = .007, other P = n.s.). BCP 
mutation was associated with lower HBV RNA level (wild type/BCP 
only/PC only/BCP + PC: 6.9/6.1/7.0/7.2 c/mL; P < .002 for BCP mu-
tation vs wild type).
3.2 | HBV RNA levels during and after PEG-
IFN treatment
In the overall population, HBV RNA levels showed a decline during 
PEG-IFN based treatment (Figure 1). Mean declines in HBV RNA level 
were −2.0/−2.3/−2.9 log c/mL at weeks 12, 24 and 52 (EOT).The mean 
HBV RNA levels were 4.0 (1.6) log c/mLat EOT and 5.0 (1.9) c/mL at 
EOF. HBV RNA was undetectable in 54% patients at EOT and in 34% 
of patients at EOF.HBV RNA early on-treatment decline differed by 
treatment regimen (Figure 2A). A significantly stronger on-treatment 
decline was observed in patients treated with PEG-IFN and LAM when 
compared to PEG-IFN monotherapy (week 12: −5.5 vs −4.2 log c/mL, 
P < .001, week 24: −5.0 vs −3.8, P < .001 and week 52: −4.7 vs −3.3, 
P < .001).At EOF, however, HBV RNA levels were similar for both treat-
ment arms (4.9 vs 5.0 log c/mL, P = .76; decline: −2.0 vs −1.8 log c/
mL, P = .71).
HBV RNA decline from baseline to EOF (week 78) was stronger 
in patients infected with HBV genotype B than in those with geno-
type C (P = .04), but did not significantly differ across the other geno-
types. By EOF, HBV RNA levels no longer differed between patients 
with wildtype virus at baseline and patients with PC and/or BCP mu-
tations (overall P = .513), but there was a trend towards lower HBV 
RNA levels in patients infected with wildtype virus when compared 
to nonwildtype virus (4.7 vs 5.3 log c/mL, P = .09).
F I G U R E  1   HBV RNA dynamics and 
detectability in the total study population 
(N = 266). The line represents mean level 
of HBV RNA (log c/mL); bars represent 
the proportion of patients with either 
detectable or undetectable HBV RNA
F I G U R E  2   Early on-treatment HBV RNA dynamics according to therapy allocation and treatment response. Lines represent mean level 
of HBV RNA (log c/mL), according to therapy allocation (A), treatment response (B) or both (C,D). Grey lines in panels c and d represent 
individual HBV RNA dynamics in patients with HBsAg loss
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F I G U R E  3   A, Individual HBV RNA 
measurements according to HBeAg loss 
at the end of follow-up. Dots represent 
individual HBV RNA measurements 
according to HBeAg loss at the end of 
follow-up, with lines representing the 
mean level of HBV RNA (log c/mL). The 
red dotted line indicates a previously 
proposed HBV DNA cut-off for the early 
identification of nonresponse (10). B, 
HBV RNA detectability according to 
HBeAg loss at the end of follow-up. Bars 
represent the proportion of patients 
with detectable or undetectable HBV 
RNA levels according to HBeAg loss at 
the end of follow-up. C, Univariable and 
multivariable diagnostic accuracy of early 
on-treatment HBV RNA for the prediction 
of HBeAg loss at the end of follow-up. 
Bars represent the area under the curve 
(AUC) for HBV RNA at baseline, week 12 
and week 24 for the prediction of HBeAg 
loss at the end of follow-up. Bars in dark 
grey represent univariable analysis; bars in 
light grey represent multivariable analysis 
adjusting for HBV genotype, ALT level, 
and presence of BCP or PC mutations. 
D, HBV RNA cut-off for the prediction 
of HBeAg loss at the end of follow-up. 
The dark line and grey line represent 
sensitivity and specificity of HBV RNA 
level for the prediction of HBeAg loss at 
the end of follow-up
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3.3 | HBV RNA level in relation to response to PEG-
IFN treatment
HBeAg loss was achieved in 49 of 136 (36%) patients treated with 
PEG-IFN monotherapy and 46 of 130 (35%) patients treated with 
PEG-IFN and LAM (P = 1.00). HBsAg became negative in 9 of 136 
(7%) and 9 of 130 (7%) patients, respectively (P = 1.00). Figure 2B-D 
show early on-treatment HBV RNA dynamics according to HBeAg 
loss, HBsAg loss and therapy allocation.
3.3.1 | HBV RNA in relation to HBeAg loss
At baseline, mean HBV RNA levels did not differ between patients with 
or without HBeAg loss at the end of follow-up (6.8 vs 6.6 log c/mL, 
P = .22; Figure 2). From week 12 onward, HBV RNA level was signifi-
cantly lower in patients who achieved HBeAg loss at EOF, (Figure 3A, 
week 12:4.4 vs 5.1 log c/mL, P = .01; week 24:3.7 vs 4.9 log c/mL, 
P < .001). Also, the rates of HBV RNA undetectability were higher in 
patients with HBeAg loss from week 24 of treatment through EOF 
(Figure 3B). HBV RNA level was independently associated with HBeAg 
loss, at all time points from week 12 onward (week 12: OR 0.75, CI-
95% 0.59-0.97, P = .02, adjusted for ALT, HBV genotype and mutations). 
When therapy allocation was introduced into the multivariable model 
(because it was not associated with HBeAg loss in univariable analy-
sis), HBV RNA level remained significantly associated with HBeAg loss 
(OR 0.55, CI-95% 0.44-0.68, P < .001). In multivariable AUROC analysis 
again adjusting for ALT, HBV genotype and mutations, HBV RNA level at 
week 24 had the highest diagnostic accuracy when compared to base-
line and week 12 (Figure 3C, AUC 0.75, CI-95% 0.67-0.84, P < .001).
The accuracy at this particular time point was AUC 0.68 after 
removing HBV RNA as a variable; the AUC was 0.79 when substi-
tuting HBV RNA by qHBsAg, the AUC was 0.78 when combining 
HBV RNA and qHBsAg, and the AUC was 0.80 when combining 
qHBsAg with HBV DNA. For the prediction of HBeAg nonre-
sponse, we aimed to identify an HBV RNA cut-off at week 12 as 
it was the earliest time point independently associated with re-
sponse. When applying the HBV RNA cut-off of 5.5 log c/mLat 
week 12, which was proposed in a recent study,11 the negative 
predictive values (NPV) for the prediction of nonresponse at the 
end of follow-up were only 76% and 73% for the total study pop-
ulation and the PEG-IFN monotherapy group, respectively. The 
performance of the cut-off was genotype-dependent, as NPVs 
for the main HBV genotypes A/B/C/D were 93/67/90/64%. Due 
to the high variance of HBV RNA results, which is illustrated in 
Figure 3A, no alternative cut-off level for the prediction of non-
response could be constructed at this time point or at week 24, 
when aiming for a prediction rule with high specificity for all HBV 
genotypes (Figure 3D). Also in subgroup analyses for genotypes 
B and D, no alternative cut-off level met this requirement (data 
not shown).
3.3.2 | HBV RNA in relation to HBsAg loss
At baseline, mean HBV RNA levels did not differ between patients 
with or without HBsAg loss at the end of follow-up (6.5 vs 6.8 log 
c/mL, P = .40). At week 12, a trend was observed towards lower 
HBV RNA levels in patients with HBsAg loss (3.8 vs 4.9 log c/mL, 
P = .11) and more HBV RNA decline from baseline (−3.2 vs −2.0 
F I G U R E  4   A, HBV RNA detectability 
according to HBsAg loss at the end 
of follow-up. Bars represent the 
proportion of patients with detectable or 
undetectable HBV RNA levels according 
to HBsAg loss at the end of follow-up. B, 
Univariable diagnostic accuracy of early 
on-treatment HBV RNA for the prediction 
of HBeAg loss at the end of follow-up. 
Bars represent the area under the curve 
(AUC) for HBV RNA at baseline, week 12 
and week 24 for the prediction of HBeAg 
loss at the end of follow-up. Because of 
the low number of patients with HBsAg 
loss, multivariable regression analysis 
could not be performed for this end point
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log c/mL, P = .06). Patients with HBsAg loss at the end of follow-
up had a significantly lower HBV RNA level at week 24 than pa-
tients without HBsAg loss (2.8 vs 4.5 log c/mL, P < .001). Also 
within the group of 95 patients who achieved HBeAg loss, HBV 
RNA at week 24 was lower in those patients who also achieved 
subsequent HBsAg loss than in those who did not (2.8 vs 3.8 log 
c/mL, P = .001). The proportion of patients with undetectable 
HBV RNA at week 24 was threefold higher in patients in the over-
all cohort with vs without HBsAg loss (Figure 4A, 89% vs 39%, 
P = .005). However, vice versa, the probability of HBsAg loss at 
the end of follow-up in patients with undetectable HBV RNA at 
week 24 was only 11%. In univariable AUROC analysis, the highest 
F I G U R E  5   A, HBV RNA, HBV DNA, qHBsAg and qHBeAg dynamics according to HBeAg loss and HBsAg loss. Boxes represent 
biomarker dynamics for HBV RNA (upper left panel), HBV DNA (upper right panel), qHBsAg (lower left panel) and qHBeAg (lower right 
panel). Dotted lines represent patients without HBeAg loss, black lines represent patients with HBeAg loss but without HBsAg loss, and 
grey lines represent patients with HBsAg loss. B, Univariable diagnostic accuracy of early on-treatment levels of various serum markers for 
the prediction of HBeAg loss at the end of follow-up. Bars represent the area under the curve (AUC) at baseline, week 12 and week 24 for 
the prediction of HBeAg loss at the end of follow-up, for HBV RNA, HBV DNA, qHBsAg, qHBeAg and ALT
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diagnostic accuracy of HBV RNA level for the prediction of HBsAg 
loss was found at week 24 (AUC 0.77, CI-95% 0.67 −0.87, P = .006, 
Figure 4B). Because HBV RNA level at week 24 was available for 
11 of 18 patients only, multivariable regression analysis could not 
be performed for this end point.
3.4 | HBV RNA dynamics in relation to dynamics of 
other biomarkers
Figure 5A shows the dynamics of HBV RNA in relation to HBV DNA, 
qHBsAg and qHBeAg, according to different definitions of treat-
ment response. All four biomarkers showed a significantly stronger 
decline—most apparent at week 24—for patients with an HBeAg loss 
when compared to patients without. Among those patients who lost 
both HBeAg and HBsAg, week 24 HBV RNA (−3.8 vs 2.8 log c/mL, 
P < .001), HBV DNA (5.9 vs 3.2, P < .002) and qHBsAg levels (−3.9 vs 
−0.2, P < .001) were all significantly lower than in those with HBeAg 
loss only. Figure 5B shows univariable AUCs for HBV DNA, qHBsAg, 
qHBeAg and ALT in relation to AUC of early on-treatment HBV RNA 
level.
4  | DISCUSSION
In this study, we investigated HBV RNA dynamics during and after 
PEG-IFN based treatment in a large multi-ethnic cohort of 266 HBeAg-
positive patients previously treated in a randomized controlled trial. 
We observed that HBV RNA is a sensitive marker for HBeAg loss and 
HBsAg loss but has low specificity. Furthermore, we could show that 
HBV RNA levels showed a stronger decrease in those HBeAg-positive 
patients who subsequently achieved HBeAg and HBsAg loss as com-
pared to those who only lost HBeAg (P = .001). The performance of a 
previously proposed HBV RNA cut-off of 5.5 log at week 12 for the 
identification of nonresponse did hold for HBV genotypes A and C.
HBV RNA in serum is particularly interesting as a biomarker be-
cause, at least in HBeAg-positive patients, it represents most likely 
a direct transcript of the HBV cccDNA. HBV RNA may therefore 
be used to monitor the effect of currently available or future ther-
apeutic agents, but also to improve the knowledge on the HBV life 
cycle. Recent reports indeed suggested that HBV RNA in serum is 
associated with response to NA therapy and PEG-IFN therapy, and 
HBV RNA has already been used to illustrate the effects of new 
compounds.7,11,15-18 A recent review highlighted the importance of 
studying this marker in multi-ethnic populations.19
In our study, we could show that HBV RNA kinetics are not 
only associated with HBeAg loss, but also with HBsAg loss, which 
represents the ultimate goal of currently available and future treat-
ments. Although a statistical prediction model for HBsAg loss was 
not possible owing to the small sample size in our study, we believe 
that the potential of HBV RNA kinetics for the prediction of a func-
tional cure should be assessed in PEG-IFN treated patient cohorts 
that include more patients who achieved HBsAg loss. HBV RNA 
monitoring should also be researched within the context of novel 
treatment approaches which target the HBV life cycle or cccDNA.
In our data set, we found that by the end of treatment, HBV 
RNA was undetectable in 54% of all patients. In line with earlier 
studies, initial HBV RNA decline was stronger in PEG-IFN combi-
nation therapy than in PEG-IFN monotherapy, but no more differ-
ence in HBV RNA level was observed 6 months after treatment 
discontinuation.7,20 The degree of HBV RNA decline in the PEG-
IFN and LAM combination group was comparable to the previ-
ously reported decline in a much smaller population treated with 
PEG-IFN in combination with adefovir, but it was weaker than re-
ported in a study comparable to ours, in which patients were also 
treated with PEG-IFN alone or in combination with LAM.7,20 This 
difference may be explained by the higher rate of HBeAg loss in 
the prior study, by the greater proportion of genotype B and D 
patients in our population, or by a different prevalence of wild-
type HBV. The correlations between HBV RNA and qHBeAg, and 
between HBV RNA and qHBsAg before treatment were also lower 
in our study, which could imply that patients may be in a different 
stage of infection.
We were able to confirm that HBV RNA level was significantly 
lower in patients with HBeAg loss than in patients without HBeAg 
loss from week 12 of treatment onward. Recently, a negative pre-
dictive value (NPV) of 93% was found for an HBV RNA cut-off of 
5.5 log c/mL to identify nonresponders in a population of individuals 
mainly infected with genotype C.20 In our study, we could confirm 
an NPV > 90% by using this cut-off for individuals with genotypes 
A and C. The NPV was lower in patients with genotypes B and D. 
Accordingly, our group recently reported that among other factors, 
HBV genotype strongly influences HBV RNA levels and also correla-
tions of HBV RNA level to other serum markers, such as qHBsAg and 
qHBeAg.21 This may explain why a universal HBV RNA cut-off did 
not allow the prediction of serological nonresponse with a desirable 
NVP > 90% in all HBV genotypes.
Construction of a clinical decision rule regardless of HBV geno-
type was hampered by a large variance in HBV RNA results, which 
was observed across all HBV genotypes irrespective of PC and BCP 
mutations, and in both patients with and without a response (data 
not shown). HBV RNA levels during PEG-IFN based treatments may 
therefore be influenced by other host or viral factors that have not 
been identified yet. One theory could be that PEG-IFN treatment 
inhibits HBeAg, HBV RNA and HBsAg formation in a different way, 
which has not been described to date. The exact mode of action 
of PEG-IFN has not completely been revealed yet, but effects in-
clude direct inhibition of transcription, epigenetic modifications of 
cccDNA, and immunomodulating effects.22-27 Novel treatments for 
HBV infections that are currently being developed mostly target the 
HBV replication cycle, and therefore, under those treatments HBV 
RNA and other HBV biomarkers may show a clearer association to 
subsequent response.
To summarize, we showed that HBV RNA in serum declines sig-
nificantly during PEG-IFN based treatment. HBV RNA level is a sen-
sitive predictor for PEG-IFN induced HBeAg loss and possibly also 
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for HBsAg loss, and may therefore be used to predict nonresponse in 
genotypes A and C. HBV RNA, however, was not a specific biomarker, 
as profound declines in HBV RNA level were also observed in patients 
without a response. Studies involving multiple HBV biomarkers, espe-
cially within the context of novel treatment approaches which target 
the HBV life cycle or cccDNA, are warranted to define more appli-
cations for this novel biomarker. As PEG-IFN is increasingly used in 
clinical trials examining new therapeutic compounds, our findings may 
also be of particular value for these studies.
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